Clinical Trial Update: Study Immunology and Safety of 60-day Treatment of SQ Grass SLIT (Sublingual Immunotherapy)-Tablet in Adult Subjects With Grass Pollen-induced Allergic Rhinoconjunctivitis [Phase 3]

View source ↗

Summary

Completed Phase 3 trial evaluating the immunology and safety of a 60-day course of SQ Grass SLIT-Tablet in adults with grass pollen–induced allergic rhinoconjun…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Grass Pollen-induced Allergic Rhinoconjunctivitis
• Seasonal Allergic Rhinitis

Drugs mentioned

• SQ Grass SLIT-Tablet

Snippet

Sponsor: Abbott | Conditions: Seasonal Allergic Rhinitis | Phase 3 | Status: COMPLETED | Results posted: 2015-12-08